+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Impact of preprocedural mitral regurgitation upon mortality after transcatheter aortic valve implantation (TAVI) for severe aortic stenosis



Impact of preprocedural mitral regurgitation upon mortality after transcatheter aortic valve implantation (TAVI) for severe aortic stenosis



Heart 100(22): 1799-1803



To identify the effects of preprocedural significant mitral regurgitation (MR) and change in MR severity upon mortality after transcatheter aortic valve implantation (TAVI) using the Edwards SAPIEN system. A retrospective analysis of 316 consecutive patients undergoing TAVI for aortic stenosis at a single centre in the UK between March 2008 and January 2013. Patients were stratified into two groups according to severity of MR: ≥grade 3 were classed as significant and ≤grade 2 were non-significant. Change in MR severity was assessed by comparison of baseline and 30-day echocardiograms. 60 patients had significant MR prior to TAVI (19.0%). These patients were of higher perioperative risk (logistic EuroScore 28.7±16.6% vs 20.3±10.7%, p=0.004) and were more dyspnoeic (New York Heart Association class IV 20.0% vs 7.4%, p=0.014). Patients with significant preprocedural MR displayed greater 12-month and cumulative mortality (28.3% vs 20.2%, log-rank p=0.024). Significant MR was independently associated with mortality (HR 4.94 (95% CI 2.07 to 11.8), p<0.001). Of the 60 patients with significant MR only 47.1% had grade 3-4 MR at 30 days (p<0.001). Patients in whom MR improved had lower mortality than those in whom it deteriorated (log-rank p=0.05). Significant MR is frequently seen in patients undergoing TAVI and is independently associated with increased all-cause mortality. Yet almost half also exhibit significant improvements in MR severity. Those who improve have better outcomes, and future work could focus upon identifying factors independently associated with such an improvement.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 053722473

Download citation: RISBibTeXText

PMID: 25155800

DOI: 10.1136/heartjnl-2014-305775


Related references

Elevation of B-Type Natriuretic Peptide at Discharge is Associated With 2-Year Mortality After Transcatheter Aortic Valve Replacement in Patients With Severe Aortic Stenosis: Insights From a Multicenter Prospective OCEAN-TAVI (Optimized Transcatheter Valvular Intervention-Transcatheter Aortic Valve Implantation) Registry. Journal of the American Heart Association 6(7), 2018

Meta-analysis of mortality outcomes and mitral regurgitation evolution in 4,839 patients having transcatheter aortic valve implantation for severe aortic stenosis. American Journal of Cardiology 114(6): 875-882, 2014

Impact and natural history of postprocedural aortic regurgitation on early and midterm mortality following transcatheter aortic valve implantation in high-risk patients with severe aortic stenosis. Journal of Cardiovascular Medicine 16(4): 286-295, 2016

Impact of mitral regurgitation on clinical outcomes of patients with low-ejection fraction, low-gradient severe aortic stenosis undergoing transcatheter aortic valve implantation. Circulation. Cardiovascular Interventions 8(2): E001895, 2015

Long-term outcomes after transcatheter aortic valve implantation in high-risk patients with severe aortic stenosis: the U.K. TAVI (United Kingdom Transcatheter Aortic Valve Implantation) Registry. Journal of the American College of Cardiology 58(20): 2130-2138, 2011

TCT-682 Impact of concomitant mitral regurgitation on mortality after transcatheter aortic valve replacement for severe aortic stenosis in high risk patients results from a prospective single center registry. Journal of the American College of Cardiology 66(15): B278-B279, 2015

Primary Mitral Valve Regurgitation Outcome in Patients With Severe Aortic Stenosis 1 Year After Transcatheter Aortic Valve Implantation: Echocardiographic Evaluation. Arquivos Brasileiros de Cardiologia 2017: 0, 2017

Transcatheter aortic valve implantation (TAVI)TAVI): A new therapeutic option for patients with severe symptomatic aortic stenosis who are not suitable or at high risk for surgical valve replacement. Deutsche Medizinische Wochenschrift 135(33): 1589-1595, 2010

Impact of transcatheter aortic valve implantation (TAVI) on pulmonary hyper-tension and clinical outcome in patients with severe aortic valvular stenosis. Clinical Research in Cardiology 104(2): 164-174, 2015

Association between valvuloarterial impedance after transcatheter aortic valve implantation and 2-year mortality in elderly patients with severe symptomatic aortic stenosis: the OCEAN-TAVI registry. Heart and Vessels 2019, 2019

The Impact of Transcatheter Aortic Valve Implantation on Mitral Regurgitation Regression in High-Risk Patients with Aortic Stenosis. Journal of Heart Valve Disease 24(4): 439-444, 2016

TCT-779 Characterization of the Impact of Transcatheter Aortic Valve Implantation on Mitral Regurgitation Regression in High Risk Patients With Aortic Stenosis. Journal of the American College of Cardiology 64(11): B227-B228, 2014

Significant reduction in mitral regurgitation after transcatheter aortic valve implantation in a patient with severe degenerative aortic valve disease, moderate to severe mitral regurgitation, and normal ejection fraction. Turk Kardiyoloji Dernegi Arsivi 40(6): 527-531, 2016

POL-TAVI First--Polish report on transcatheter aortic valve implantation (TAVI) of Edwards-Sapien prosthesis in the first 19 high risk patients with severe aortic stenosis and comorbidities. Kardiologia Polska 67(8): 936-940, 2010

Impact of preoperative mitral regurgitation on outcome after Transcatheter Aortic Valve Implantation: results of the German TAVI registry. European Heart Journal 34(Suppl 1): 2581-2581, 2013